Literature DB >> 11251976

Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Valpha14 NKT cells.

T Shin1, T Nakayama, Y Akutsu, S Motohashi, Y Shibata, M Harada, N Kamada, C Shimizu, E Shimizu, T Saito, T Ochiai, M Taniguchi.   

Abstract

A unique lymphocyte lineage, the Valpha14 NKT cells, expresses both NK1.1 and an invariant antigen receptor encoded by Valpha14 and Jalpha281 gene segments. Valpha14 NKT cells play crucial roles in various immune responses, including autoimmune diseases, allergic reactions and anti-tumor immunity. Valpha14 NKT cells were demonstrated to be essential for anti-tumor effect of IL-12 in vivo. Here, we report that adoptive transfer of IL-12-activated Valpha14 NKT cells prevents hepatic metastasis of B16 melanoma. The injection of large amounts of IL-2, IL-4, and IFN-gamma, which are cytokines produced by activated Valpha14 NKT cells, exhibited no significant inhibition of the metastasis of this melanoma. The cells prepared from the liver of IL-12-injected mice expressed a potent cytotoxic activity on B16 melanoma cells in vitro. Although the adoptive transfer of IL-12-activated Valpha14 NKT cells prevents hepatic metastasis of B16 melanoma, activated NK cells from IL-12-injected RAG-1-/- mice failed to inhibit the metastasis of this melanoma. Thus, the anti-tumor effect of IL-12 can be replaced by adoptive transfer of IL-12-activated Valpha14 NKT cells but not by IL-12-activated NK cells, suggesting a minor role of NK cells for the IL-12-mediated anti-tumor effect in this experimental system. Moreover, our studies have suggested the involvement of direct cytotoxic mechanisms rather than cytokine-mediated immune responses at the effector phase of the Valpha14 NKT cell-mediated anti-tumor activity. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11251976     DOI: 10.1002/1097-0215(20010215)91:4<523::aid-ijc1087>3.0.co;2-l

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

1.  Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.

Authors:  Mark A Exley; Phillip Friedlander; Nadia Alatrakchi; Lianne Vriend; Simon Yue; Tetsuro Sasada; Wanyong Zeng; Yo Mizukami; Justice Clark; David Nemer; Kenneth LeClair; Christine Canning; Heather Daley; Glenn Dranoff; Anita Giobbie-Hurder; F Stephen Hodi; Jerome Ritz; Steven P Balk
Journal:  Clin Cancer Res       Date:  2017-02-13       Impact factor: 12.531

Review 2.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

Review 3.  Glycolipid targets of CD1-mediated T-cell responses.

Authors:  D B Moody; G S Besra
Journal:  Immunology       Date:  2001-11       Impact factor: 7.397

Review 4.  NKG2D ligands as therapeutic targets.

Authors:  Paul Spear; Ming-Ru Wu; Marie-Louise Sentman; Charles L Sentman
Journal:  Cancer Immun       Date:  2013-05-01

5.  Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell.

Authors:  Hiroyasu Ito; Mitsuru Seishima
Journal:  J Biomed Biotechnol       Date:  2010-05-19

Review 6.  Natural Killer T Cells in Cancer Immunotherapy.

Authors:  Shiny Nair; Madhav V Dhodapkar
Journal:  Front Immunol       Date:  2017-09-22       Impact factor: 7.561

Review 7.  Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.

Authors:  Reem Ghinnagow; Luis Javier Cruz; Elodie Macho-Fernandez; Christelle Faveeuw; François Trottein
Journal:  Front Immunol       Date:  2017-07-27       Impact factor: 7.561

8.  Expansion of lung V alpha 14 NKT cells by administration of alpha-galactosylceramide-pulsed dendritic cells.

Authors:  Yasunori Akutsu; Toshinori Nakayama; Michishige Harada; Tetsu Kawano; Shinichiro Motohashi; Eiko Shimizu; Toshihiro Ito; Noriaki Kamada; Takeshi Saito; Hisahiro Matsubara; Yukimasa Miyazawa; Takenori Ochiai; Masaru Taniguchi
Journal:  Jpn J Cancer Res       Date:  2002-04

9.  Natural killer T cells subsets in cancer, functional defects in prostate cancer and implications for immunotherapy.

Authors:  Michael Nowak; Ingo G H Schmidt-Wolf
Journal:  Cancers (Basel)       Date:  2011-09-20       Impact factor: 6.639

Review 10.  Novel Approaches to Exploiting Invariant NKT Cells in Cancer Immunotherapy.

Authors:  Benjamin J Wolf; Jiyoung Elizabeth Choi; Mark A Exley
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.